Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.
Another day, another industry damaged by the president-elect's rhetoric. But these three companies are strong enough to overcome arm-twisting over drug prices.
Lilly's sola study did not reduce amyloid plaques in the brain, adding to the likelihood that Biogen's late-stage Alzheimer's study will prove successful.
The drugmaker is down nearly 46% year to date, which has created a great buying opportunity.
Shares are Biogen spiked on the aducanumab data leak as investors with unfair access to what was supposed to be embargoed results traded on the information.
Risk-tolerant investors should consider buying this stock on further dips.
A clinical trial of Voyager Therapeutics' gene therapy is showing improvement in Parkinson's patients.
In an interview, the president-elect said that he will bring down pharmaceutical prices.